HolderBook

PSP Research LLC

Reported holdings as of Q2 2026, from 3 quarterly filings.

CIK
2106939
Reported value
$187.9M
Positions
75
Top 10 weight
88.0%
Filed
2026-07-09
Days after quarter end
9

Holdings

SecurityTickerValue SharesWeightWeight change Held Change
SPDR SERIES TRUSTXBI$90.2M570,00048.01%+22.26pp2q+100.1%+$45.1M
ISHARES TRSGOV$70.5M700,00037.51%-12.35pp3qHELD
ROYALTY PHARMA PLCRPRX$616.8K11,0000.33%-0.05pp3qHELD
NURIX THERAPEUTICS INCNRIX$606.5K25,0000.32%+0.01pp3q-12.9%-$89.8K
INCYTE CORPINCY$600.8K5,3000.32%-0.03pp3qHELD
ARGENX SEARGX$594.7K6410.32%-0.01pp3qHELD
DISC MEDICINE INCIRON$585.1K8,0000.31%-0.05pp2qHELD
RAPPORT THERAPEUTICS INCRAPP$583.4K14,0000.31%flat3qHELD
ULTRAGENYX PHARMACEUTICAL INRARE$567.6K17,0000.30%-0.03pp2q-23.1%-$170.3K
TREVI THERAPEUTICS INCTRVI$559.5K30,0000.30%+0.04pp2qHELD
MONTE ROSA THERAPEUTICS INCGLUE$556.6K23,0000.30%-0.03pp2q-17.9%-$121.0K
TG THERAPEUTICS INCTGTX$549.4K10,0000.29%-0.01pp3q-23.1%-$164.8K
HALOZYME THERAPEUTICS INCHALO$547.9K7,0000.29%-0.08pp3q-12.8%-$80.3K
IONIS PHARMACEUTICALS INCIONS$539.2K6,8000.29%-0.07pp3qHELD
PHARVARIS N VPHVS$518.7K15,0000.28%-0.12pp3q-25.0%-$172.9K
ARCUTIS BIOTHERAPEUTICS INCARQT$516.5K19,7000.27%-0.05pp3qHELD
AURINIA PHARMACEUTICALS INCAUPH$509.1K30,0000.27%-0.04pp3qHELD
NEUROCRINE BIOSCIENCES INCNBIX$505.6K3,0000.27%-0.09pp3q-22.0%-$142.9K
IMMUNOVANT INCIMVT$500.9K13,0000.27%-0.07pp3q-32.3%-$238.9K
ACADIA PHARMACEUTICALS INCACAD$500.1K19,7660.27%-0.05pp3qHELD
PTC THERAPEUTICS INCPTCT$489.4K6,0000.26%-0.03pp3qHELD
CELLDEX THERAPEUTICS INC NEWCLDX$483.7K13,0000.26%-0.03pp3qHELD
IMMUNOCORE HLDGS PLCIMCR$480.7K15,1410.26%-0.07pp3qHELD
DEFINIUM THERAPEUTICS INCDFTX$470.4K10,0000.25%-0.22pp2q-71.3%-$1.2M
COGENT BIOSCIENCES INCCOGT$464.4K12,0000.25%-0.08pp3qHELD
KYMERA THERAPEUTICS INCKYMR$458.7K4,0000.24%-0.13pp3q-36.5%-$263.7K
DYNE THERAPEUTICS INCDYN$444.2K20,0000.24%-0.02pp3qHELD
ALNYLAM PHARMACEUTICALS INCALNY$441.0K1,4650.23%-0.11pp3qHELD
TARSUS PHARMACEUTICALS INCTARS$440.6K7,0000.23%-0.11pp3qHELD
SYNDAX PHARMACEUTICALS INCSNDX$437.2K20,0000.23%-0.10pp3qHELD
EXELIXIS INCEXEL$435.3K8,0000.23%-0.13pp3q-33.0%-$214.8K
CRINETICS PHARMACEUTICALS INCRNX$411.6K11,0000.22%-0.06pp3qHELD
NEWAMSTERDAM PHARMA COMPANYNAMS$406.7K12,0000.22%-0.12pp3q-20.0%-$101.7K
ASCENDIS PHARMA A/SASND$400.1K1,5000.21%-newNEW
LIQUIDIA CORPORATIONLQDA$398.6K5,0000.21%-newNEW
STOKE THERAPEUTICS INCSTOK$392.6K12,0000.21%-0.07pp3qHELD
VIKING THERAPEUTICS INCVKTX$390.1K10,0000.21%-0.14pp3q-33.3%-$195.1K
IMMUNOME INCIMNM$381.4K18,0000.20%-0.11pp3q-10.0%-$42.4K
PROTAGONIST THERAPEUTICS INCPTGX$367.7K3,0000.20%-0.03pp3qHELD
HARMONY BIOSCIENCES HLDGS INHRMY$364.1K10,0000.19%-0.09pp3q-30.0%-$155.9K
ENLIVEN THERAPEUTICS INCELVN$355.2K7,0000.19%-0.01pp2qHELD
SPYRE THERAPEUTICS INCSYRE$355.1K4,0000.19%flat3q-22.5%-$102.9K
INTELLIA THERAPEUTICS INCNTLA$338.4K20,0000.18%-0.06pp2q-25.7%-$116.7K
MADRIGAL PHARMACEUTICALS INCMDGL$322.2K6000.17%-0.05pp3qHELD
KINIKSA PHARMACEUTICALS INTLKNSA$319.8K5,0000.17%-0.14pp3q-44.4%-$255.8K
ALKERMES PLCALKS$314.4K6,0000.17%+0.02pp3qHELD
TANGO THERAPEUTICS INCTNGX$312.6K10,0000.17%-0.05pp2q-30.6%-$137.5K
ARDELYX INCARDX$306.0K60,0000.16%-0.18pp2q-25.0%-$102.0K
VERA THERAPEUTICS INCVERA$300.4K7,0000.16%-0.12pp3q-30.0%-$128.7K
MIRUM PHARMACEUTICALS INCMIRM$292.7K2,5000.16%-0.17pp3q-50.0%-$292.7K
ORUKA THERAPEUTICS INCORKA$285.5K3,0000.15%-0.02pp2q-39.6%-$187.3K
SUPERNUS PHARMACEUTICALSSUPN$279.1K6,0000.15%-0.07pp3qHELD
CRISPR THERAPEUTICS AGCRSP$272.7K5,0000.15%-0.17pp3q-47.4%-$245.4K
ZYMEWORKS INCZYME$261.4K10,0000.14%-0.04pp3qHELD
KRYSTAL BIOTECH INCKRYS$257.2K6920.14%-newNEW
COMPASS PATHWAYS PLCCMPS$254.7K18,0000.14%-0.14pp2q-74.6%-$750.0K
XENON PHARMACEUTICALS INCXENE$253.5K4,2000.13%-0.04pp3qHELD
AXSOME THERAPEUTICS INCAXSM$244.8K1,0000.13%-0.21pp2q-64.9%-$451.6K
ARRIVENT BIOPHARMA INCAVBP$244.6K7,0410.13%-newNEW
DIANTHUS THERAPEUTICS INCDNTH$243.7K2,5000.13%-0.17pp3q-50.0%-$243.7K
JAZZ PHARMACEUTICALS PLCJAZZ$234.0K9710.12%-newNEW
KODIAK SCIENCES INCKOD$233.8K6,0000.12%-0.15pp3q-40.0%-$155.8K
REVOLUTION MEDICINES INCRVMD$224.7K1,2000.12%-newNEW
BRIDGEBIO PHARMA INCBBIO$223.4K3,0000.12%-0.20pp3q-50.0%-$223.4K
RHYTHM PHARMACEUTICALS INCRYTM$222.1K2,0000.12%-newNEW
DENALI THERAPEUTICS INCDNLI$217.7K8,4630.12%-newNEW
ARROWHEAD PHARMACEUTICALS INARWR$211.9K2,6000.11%-newNEW
SCHOLAR ROCK HLDG CORPSRRK$210.5K3,8270.11%-newNEW
EDGEWISE THERAPEUTICS INCEWTX$203.2K5,0000.11%-0.04pp2q-23.1%-$60.9K
AMYLYX PHARMACEUTICALS INCAMLX$194.7K10,8380.10%flat3qHELD
CYTOMX THERAPEUTICS INCCTMX$147.8K39,4000.08%-newNEW
OCULAR THERAPEUTIX INCOCUL$147.3K15,0000.08%-0.01pp3qHELD
EYEPOINT INCEYPT$143.0K10,0000.08%-0.02pp3qHELD
ORIC PHARMACEUTICALS INCORIC$140.8K13,0000.07%-0.04pp2qHELD
OLEMA PHARMACEUTICALS INCOLMA$125.1K10,0000.07%-0.04pp3qHELD

By sector

Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.

Biotech & Pharma 14.5%Not classified 85.5%
 
SectorValueShare
Biotech & Pharma$27.2M14.5%
Not classified$160.7M85.5%

Quarter by quarter

QuarterValuePositions NewAddedTrimmed ExitedTop 10 Days to file
Q2 2026$187.9M75111301588.0%9
Q1 2026$141.3M79219402781.9%17
Q4 2025$114.4M85000065.8%37

Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.

Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.

Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.